J Clin Lipidol
-
To review efficacy and safety data of 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (also known as statins) in adult patients with chronic liver disease. ⋯ Available clinical data suggest that statin therapy in nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and hepatitis C virus is a safe option in the management of dyslipidemia.
-
Biography Historical Article
Remembering William B. Kannel, MD, MPH (1923-2011).
-
Randomized Controlled Trial
Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.
Many patients who could benefit from hydroxymethylglutaryl coenzyme-A reductase inhibitors (statins) are unable to take statins because of myalgias while taking previous statin therapy. ⋯ Once-weekly low-dose rosuvastatin is an effective and well-tolerated lipid-lowering therapy option for patients not at LDL goal and previously unable to tolerate statins because of a history of myalgias.
-
Muscle pain without elevation of serum creatine phosphokinase (CPK) (myalgia) is the most common medication-related adverse effect of statin therapy; it occurs in up to 10% of patients who are prescribed statin therapy. Although much is known regarding risk factors for overt myositis, very few studies have provided information on this common form of statin intolerance. ⋯ Statin intolerance attributable to myalgia is a significant barrier to effective treatment of hyperlipidemia. Conventional clinical risk factors for myositis do not appear to predictive of statin-associated myalgia. These findings underscore the need to better define the pathophysiology of statin-induced myalgia and develop methodologies to guide treatment of statin-intolerant patients.